LYTIR

Company · REGN

Regeneron Pharmaceuticals, Inc.

Name as listed on its exchange; filed with the SEC as REGENERON PHARMACEUTICALS, INC.

Nasdaq's symbol directory lists REGN on Nasdaq as “Regeneron Pharmaceuticals, Inc. - Common Stock”.

In the 12 months to Nov 19, 2026: insiders sold on 19 occasions ($60.3M); 20 planned-sale notices; 3 congressional trade disclosures; 6 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $60.3M in total.Jul: Insider sales $130KAug: Insider sales $960KSep: Insider sales $2.3MOct: Insider sales $6.2MNov: Insider sales $50.6MDecJanFebMarAprMayJunJulAugSepOctNov$50.6M
Insider purchases above the line: $0Insider sales below: $60.3M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. George L. Sing sold on 3 days latest Nov 17, 2026 sold $22.3M
  2. Andrew J. Murphy, Co-Chief Scientific Officer sold on 2 days all under a 10b5-1 plan latest Nov 17, 2026 sold $8.0M
  3. Huda Y. Zoghbi sold on 2 days 1 of them under a 10b5-1 plan latest Nov 3, 2026 sold $7.9M
  4. Christine A. Poon sold on 1 day latest Nov 2, 2026 sold $7.6M
  5. Joseph J. LaRosa, EVP General Counsel and Secret sold on 1 day latest Nov 2, 2026 sold $4.3M
  6. Jason Pitofsky, SVP Controller sold on 1 day latest Nov 4, 2026 sold $3.8M
  7. Marion McCourt, EVP Commercial sold on 4 days all under a 10b5-1 plan latest Nov 16, 2026 sold $3.5M
  8. Michael S. Brown sold on 1 day all under a 10b5-1 plan latest Oct 30, 2026 sold $1.7M
  9. Kathryn Guarini sold on 3 days all under a 10b5-1 plan latest Oct 30, 2026 sold $1.0M
  10. RYAN ARTHUR F sold on 1 day all under a 10b5-1 plan latest Jul 2, 2026 sold $130K
Every trade (19)
  1. SELLAndrew J. Murphy, Co-Chief Scientific Officer sold Nov 17, 2026 5,011 shares 16 legs combined 10b5-1 plan (scheduled) filing $4.8M
  2. SELLGeorge L. Sing sold Nov 17, 2026 1,000 shares 3 legs combined filing $958K
  3. SELLGeorge L. Sing sold Nov 16, 2026 1,000 shares filing $960K
  4. SELLMarion McCourt, EVP Commercial sold Nov 16, 2026 566 shares 13 legs combined 10b5-1 plan (scheduled) filing $544K
  5. SELLJason Pitofsky, SVP Controller sold Nov 4, 2026 4,062 shares 8 legs combined filing $3.8M
  6. SELLHuda Y. Zoghbi sold Nov 3, 2026 7,439 shares 2 legs combined filing $7.2M
  7. SELLGeorge L. Sing sold Nov 2, 2026 21,129 shares 9 legs combined filing $20.4M
  8. SELLChristine A. Poon sold Nov 2, 2026 7,830 shares 6 legs combined filing $7.6M
  9. SELLJoseph J. LaRosa, EVP General Counsel and Secret sold Nov 2, 2026 4,466 shares 2 legs combined filing $4.3M
  10. SELLMichael S. Brown sold Oct 30, 2026 1,929 shares 10b5-1 plan (scheduled) filing $1.7M
  11. SELLMarion McCourt, EVP Commercial sold Oct 30, 2026 1,132 shares 10b5-1 plan (scheduled) filing $984K
  12. SELLKathryn Guarini sold Oct 30, 2026 400 shares 10b5-1 plan (scheduled) filing $360K
  13. SELLAndrew J. Murphy, Co-Chief Scientific Officer sold Oct 14, 2026 4,147 shares 27 legs combined 10b5-1 plan (scheduled) filing $3.2M
  14. SELLMarion McCourt, EVP Commercial sold Sep 3, 2026 1,131 shares 10b5-1 plan (scheduled) filing $970K
  15. SELLMarion McCourt, EVP Commercial sold Sep 2, 2026 1,215 shares 10b5-1 plan (scheduled) filing $1.0M
  16. SELLKathryn Guarini sold Sep 2, 2026 400 shares 10b5-1 plan (scheduled) filing $340K
  17. SELLHuda Y. Zoghbi sold Aug 10, 2026 800 shares 10b5-1 plan (scheduled) filing $640K
  18. SELLKathryn Guarini sold Aug 10, 2026 400 shares 10b5-1 plan (scheduled) filing $320K
  19. SELLRYAN ARTHUR F sold Jul 2, 2026 200 shares 10b5-1 plan (scheduled) filing $130K

Planned sales · SEC Form 144

Notice given

A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice

  1. MURPHY ANDREW J filed Nov 17, 2026 Officer 5,011 shares planned sale date 11/17/2026 filing $4.8M
  2. GEORGE L. SING filed Nov 17, 2026 Director 1,000 shares planned sale date 11/17/2026 filing $958K
  3. GEORGE L. SING filed Nov 16, 2026 Director 1,000 shares planned sale date 11/16/2026 filing $960K
  4. McCourt Marion filed Nov 16, 2026 Officer 566 shares planned sale date 11/16/2026 filing $545K
  5. Jason Pitofsky filed Nov 4, 2026 Officer 3,883 shares planned sale date 11/04/2026 filing $3.8M
  6. Jason Pitofsky filed Nov 4, 2026 Officer 180 shares planned sale date 11/04/2026 filing $175K
  7. Huda Zoghbi filed Nov 3, 2026 Director 7,439 shares planned sale date 11/03/2026 filing $7.2M
  8. GEORGE L. SING filed Nov 2, 2026 Director 21,129 shares planned sale date 11/02/2026 filing $20.4M
  9. Christine Poon filed Nov 2, 2026 Director 7,830 shares planned sale date 11/02/2026 filing $7.5M
  10. Joseph LaRosa filed Nov 2, 2026 Officer 4,466 shares planned sale date 11/02/2026 filing $4.3M
  11. MICHAEL S BROWN filed Oct 30, 2026 Director 1,929 shares planned sale date 10/30/2026 filing $1.6M
  12. McCourt Marion filed Oct 30, 2026 Officer 1,132 shares planned sale date 10/30/2026 filing $984K
  13. Guarini Kathryn filed Oct 30, 2026 Director 400 shares planned sale date 10/30/2026 filing $360K
  14. MURPHY ANDREW J filed Oct 14, 2026 Officer 4,147 shares planned sale date 10/14/2026 filing $3.2M
  15. McCourt Marion filed Sep 3, 2026 Officer 1,131 shares planned sale date 09/03/2026 filing $969K
  16. McCourt Marion filed Sep 2, 2026 Officer 1,215 shares planned sale date 09/02/2026 filing $1.0M
  17. Guarini Kathryn filed Sep 2, 2026 Director 400 shares planned sale date 09/02/2026 filing $340K
  18. Zoghbi Huda Y filed Aug 10, 2026 Director 800 shares planned sale date 08/10/2026 filing $640K
  19. Guarini Kathryn filed Aug 10, 2026 Board member 400 shares planned sale date 08/10/2026 filing $320K
  20. Arthur F. Ryan filed Jul 2, 2026 Director 400 shares planned sale date 07/02/2026 filing $250K

Congress · STOCK Act

The Althing

Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.

  1. Gilbert Cisneros (D-CA31): Sale May 15, 2026 reported Jun 8, 2026 one of 103 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000
  2. Alan Armstrong (R-OK): Purchase Mar 27, 2026 reported Jul 21, 2026 one of 703 trades the member reported that day Senate Stock $1,001 - $15,000
  3. Julia Letlow (R-LA05): Purchase Feb 12, 2026 reported Mar 12, 2026 one of 33 trades the member reported that day House Stocks (including ADRs) $1,001 - $15,000

Executive branch · OGE Form 278-T

Reported by the President

8 confirmed trades on scanned reports whose security name matches this company's own filed name exactly (letter case, punctuation and Inc/Corp-style endings aside). All of Donald J. Trump's reports

  1. Purchase: REGENERON PHARMACEUTICALS INC Jul 23, 2026 reported Sep 8, 2026 President Donald J. Trump Periodic Transaction Report 09.08.26 $50,001 – $100,000
  2. Purchase: REGENERON PHARMACEUTICALS INC Jul 17, 2026 reported Sep 8, 2026 President Donald J. Trump Periodic Transaction Report 09.08.26 $1,001 – $15,000
  3. Sale: REGENERON PHARMACEUTICALS INC Jun 16, 2026 reported Aug 12, 2026 President Donald J. Trump Periodic Transaction Report 08.12.26 $1,001 – $15,000
  4. Sale: REGENERON PHARMACEUTICALS INC Jun 12, 2026 reported Aug 12, 2026 President Donald J. Trump Periodic Transaction Report 08.12.26 $100,001 – $250,000
  5. Purchase: REGENERON PHARMACEUTICALS INC May 11, 2026 reported Jun 25, 2026 President Donald J. Trump Periodic Transaction Report 06.25.26 (2) $100,001 – $250,000
  6. Purchase: REGENERON PHARMACEUTICALS INC Apr 27, 2026 reported Jun 25, 2026 President Donald J. Trump Periodic Transaction Report 06.25.26 (1) $15,001 – $50,000
  7. Purchase: REGENERON PHARMACEUTICALS INC Apr 15, 2026 reported Jun 25, 2026 President Donald J. Trump Periodic Transaction Report 06.25.26 (1) $1,001 – $15,000
  8. Purchase: REGENERON PHARMACEUTICALS INC Apr 7, 2026 reported Jun 25, 2026 President Donald J. Trump Periodic Transaction Report 06.25.26 (1) $1,001 – $15,000

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Results of operations and financial condition filing Oct 30, 2026
  2. Entry into a material definitive agreement; Results of operations and financial condition; Other events filing Oct 6, 2026
  3. Departure or appointment of directors or officers filing Sep 30, 2026
  4. Results of operations and financial condition filing Jul 30, 2026
  5. Results of operations and financial condition filing Jul 6, 2026
  6. Submission of matters to a vote of security holders filing Jun 17, 2026

Lobbying · Senate LDA reports

Lobbying filed

12 quarterly lobbying reports for 2026 naming Regeneron Pharmaceuticals, Inc. as the client: 2 filed by the company itself, 10 by outside firms it hired. Each line is one report as filed; an amended report is a line of its own. An outside firm states what the company paid it; the company's own report states its whole lobbying spend, which can include those fees, so the lines are not added up. Reports are collected in batches and a quarter can be missing here; the full record is at lda.gov.

  1. The company itself Q2 2026 filing $630K
  2. BGR GOVERNMENT AFFAIRS Q2 2026 filing $90K
  3. CHECKMATE GOVERNMENT RELATIONS Q2 2026 filing $90K
  4. CRANE STRATEGIES Q2 2026 filing $50K
  5. ARNOLD & PORTER KAYE SCHOLER LLP Q2 2026 filing $50K
  6. THE WASHINGTON TAX & PUBLIC POLICY GROUP Q2 2026 filing $30K
  7. The company itself Q1 2026 filing $640K
  8. BGR GOVERNMENT AFFAIRS Q1 2026 filing $90K
  9. CHECKMATE GOVERNMENT RELATIONS Q1 2026 filing $90K
  10. CRANE STRATEGIES Q1 2026 filing $50K
  11. THE WASHINGTON TAX & PUBLIC POLICY GROUP Q1 2026 filing $30K
  12. ARNOLD & PORTER KAYE SCHOLER LLP Q1 2026 filing no amount stated

Sources: SEC EDGAR (Forms 4, 144 and 8-K), Senate LDA lobbying reports, OGE Form 278-T reports on whitehouse.gov and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.